Compare DWSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | CRDF |
|---|---|---|
| Founded | 1952 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 114.2M |
| IPO Year | 1995 | 2012 |
| Metric | DWSN | CRDF |
|---|---|---|
| Price | $4.26 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 106.4K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | 27.37 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $145,773,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.27 | $1.35 |
| 52 Week High | $5.54 | $4.56 |
| Indicator | DWSN | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 43.70 |
| Support Level | $1.63 | N/A |
| Resistance Level | $4.93 | $1.76 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 75.97 | 26.15 |
Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.